Clinical Trial Update: LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of LGX818 and MEK162 in combination with a third agent in advanced BRAF-mutant melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BGJ398 (BGJ398)
• BKM120 (Buparlisib)
• INC280
• LEE011 (ribociclib)
• LGX818 (encorafenib)
• MEK162 (binimetinib)

Snippet

Sponsor: Pfizer | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-05